Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~2 h
Time for 50 % to be eliminated
Steady State
~9 h
≈ 4.3 half-lives
Accumulation
×1.00
Cmax at steady state ÷ Cmax first dose
Gone After
~14 h
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 59.5 | 0 |
| 119 | 0 |
| 173.542 | 14.7 |
| 233.042 | 0 |
| 292.542 | 0 |
| 347.083 | 2.1 |
| 406.583 | 0 |
| 466.083 | 0 |
| 520.625 | 0.3 |
| 580.125 | 0 |
| 639.625 | 0 |
| 694.167 | 0 |
| 753.667 | 0 |
| 813.167 | 0 |
| 867.708 | 0 |
| 927.208 | 0 |
| 986.708 | 0 |
| 1041.25 | 0 |
| 1100.75 | 0 |
| 1160.25 | 0 |
Source: Literature estimate. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Melanotan II: ~2 hours.
Melanotan II has a reported half-life of about 2 hours. With a dosing frequency of two to three times per week, each dose clears almost entirely before the next, making accumulation essentially negligible. Steady state, if dosing were continuous, would be reached at roughly 4.3 half-lives, about 9 hours.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 14 hours, seven half-lives.
Melanotan II is a synthetic melanocortin receptor agonist studied for its effects on melanogenesis. Typical doses range from 0.1 to 1 mg administered two to three times per week. Because of the short half-life relative to the dosing interval, each injection acts independently, and the pharmacokinetic profile is straightforward.